Accessibility Menu
Vir Biotechnology Stock Quote

Vir Biotechnology (NASDAQ: VIR)

$5.78
(-5.6%)
-0.34
Price as of October 23, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$5.78
Daily Change
(-5.6%) $0.34
Day's Range
$5.75 - $6.19
Previous Close
$5.78
Open
$6.09
Beta
1.25
Volume
4,662,034
Average Volume
1,296,695
Market Cap
850.2M
Market Cap / Employee
$6.12M
52wk Range
$4.16 - $14.45
Revenue
-
Gross Margin
0.35%
Dividend Yield
N/A
EPS
-$4.01
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Vir Biotechnology Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
VIR-23.14%-83.35%-30.12%-56%
S&P+14.5%+93.32%+14.09%+126%

Vir Biotechnology Company Info

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$1.21M-60.5%
Gross Profit-$1.71M-38.6%
Gross Margin-141.19%-101.0%
Market Cap$696.72M-42.5%
Market Cap / Employee$1.71M0.0%
Employees408-30.5%
Net Income-$110.96M19.8%
EBITDA-$105.69M15.5%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$299.32M-3.7%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$93.41M-1.7%
Short Term Debt$8.83M-54.7%

Ratios

Q2 2025YOY Change
Return On Assets-38.45%-13.8%
Return On Invested Capital-11.82%-0.2%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$122.76M-56.4%
Operating Free Cash Flow-$120.22M-54.4%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book0.830.810.770.67-14.68%
Price to Sales13.0213.5342.7036.73138.91%
Price to Tangible Book Value0.850.830.790.68-14.82%
Enterprise Value to EBITDA-0.62-1.11-0.72-1.00-22.71%
Return on Equity-36.6%-38.1%-44.6%-46.2%55.18%
Total Debt$112.81M$97.89M$96.10M$102.23M-10.73%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.